×
Galera Therapeutics EBITDA 2018-2024 | GRTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Galera Therapeutics ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Galera Therapeutics EBITDA 2018-2024 | GRTX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Galera Therapeutics ebitda from 2018 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$139.4B
Bristol Myers Squibb (BMY)
$115.2B
Gilead Sciences (GILD)
$114.5B
Vertex Pharmaceuticals (VRTX)
$104.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$78.6B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$37.4B
Alnylam Pharmaceuticals (ALNY)
$30.1B
BioNTech SE (BNTX)
$27.6B
Biogen (BIIB)
$21.9B
Illumina (ILMN)
$20.8B
Moderna (MRNA)
$16.2B
Genmab (GMAB)
$13.9B
Incyte (INCY)
$13.4B
BioMarin Pharmaceutical (BMRN)
$12.7B
Insmed (INSM)
$12.5B
Sarepta Therapeutics (SRPT)
$11.9B
Bio-Techne Corp (TECH)
$11.4B
Exact Sciences (EXAS)
$10.5B
Vaxcyte (PCVX)
$10.4B
QIAGEN (QGEN)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8B
Jazz Pharmaceuticals (JAZZ)
$7.5B